SG11202010237RA - Fusion protein binding to cd47 protein and application thereof - Google Patents

Fusion protein binding to cd47 protein and application thereof

Info

Publication number
SG11202010237RA
SG11202010237RA SG11202010237RA SG11202010237RA SG11202010237RA SG 11202010237R A SG11202010237R A SG 11202010237RA SG 11202010237R A SG11202010237R A SG 11202010237RA SG 11202010237R A SG11202010237R A SG 11202010237RA SG 11202010237R A SG11202010237R A SG 11202010237RA
Authority
SG
Singapore
Prior art keywords
protein
application
binding
fusion protein
fusion
Prior art date
Application number
SG11202010237RA
Inventor
Ming Lv
Xiaoran Ding
Shiwei Miao
Bin Tan
Xuegong Wang
Original Assignee
Hangzhou Sumgen Biotech Co Ltd
Sumgen Mab Beijing Biotech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Sumgen Biotech Co Ltd, Sumgen Mab Beijing Biotech Co Ltd filed Critical Hangzhou Sumgen Biotech Co Ltd
Publication of SG11202010237RA publication Critical patent/SG11202010237RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/02—Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds
    • C40B40/06—Libraries containing nucleotides or polynucleotides, or derivatives thereof
    • C40B40/08—Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202010237RA 2018-04-17 2019-04-16 Fusion protein binding to cd47 protein and application thereof SG11202010237RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810343482.9A CN110386984B (en) 2018-04-17 2018-04-17 Fusion protein combined with CD47 protein and application thereof
PCT/CN2019/082863 WO2019201236A1 (en) 2018-04-17 2019-04-16 Fusion protein binding to cd47 protein and application thereof

Publications (1)

Publication Number Publication Date
SG11202010237RA true SG11202010237RA (en) 2020-11-27

Family

ID=68239336

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202010237RA SG11202010237RA (en) 2018-04-17 2019-04-16 Fusion protein binding to cd47 protein and application thereof

Country Status (11)

Country Link
US (1) US11891423B2 (en)
EP (1) EP3795595A4 (en)
JP (1) JP2021520830A (en)
KR (1) KR20210003766A (en)
CN (2) CN110386984B (en)
AU (1) AU2019256177A1 (en)
BR (1) BR112020021294A2 (en)
CA (1) CA3097417A1 (en)
SG (1) SG11202010237RA (en)
TW (1) TWI822760B (en)
WO (1) WO2019201236A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7454645B2 (en) 2019-07-16 2024-03-22 ギリアード サイエンシーズ， インコーポレイテッド HIV vaccine and its production and use methods
CA3153501A1 (en) 2019-10-18 2021-04-22 Forty Seven, Inc. Combination therapies for treating myelodysplastic syndromes and acute myeloid leukemia
EP4052040A1 (en) 2019-10-31 2022-09-07 Forty Seven, Inc. Anti-cd47 and anti-cd20 based treatment of blood cancer
BR112022012625A2 (en) 2019-12-24 2022-09-06 Carna Biosciences Inc DIACYLGLYCEROL KINASE MODULATING COMPOUNDS
CN115087488A (en) 2020-02-14 2022-09-20 震动疗法股份有限公司 Antibodies and fusion proteins binding to CCR8 and uses thereof
CN111253482B (en) * 2020-02-18 2021-11-30 中国人民解放军军事科学院军事医学研究院 SIRPa variants, fusion proteins, and uses thereof
CN111808183B (en) * 2020-07-25 2022-07-08 北京吉尔麦迪生物医药科技有限公司 High-affinity SIRP alpha mutant targeting CD47 and fusion protein thereof
KR102398032B1 (en) * 2020-09-22 2022-05-19 비피진 주식회사 5'-nucleotidas variants for treatment cancer
EP4304633A1 (en) 2021-03-12 2024-01-17 Mendus B.V. Methods of vaccination and use of cd47 blockade
TW202302145A (en) 2021-04-14 2023-01-16 美商基利科學股份有限公司 Co-inhibition of cd47/sirpα binding and nedd8-activating enzyme e1 regulatory subunit for the treatment of cancer
CA3222439A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
CA3222595A1 (en) 2021-06-23 2022-12-29 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
EP4359389A1 (en) 2021-06-23 2024-05-01 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
US11976072B2 (en) 2021-06-23 2024-05-07 Gilead Sciences, Inc. Diacylglycerol kinase modulating compounds
CA3234909A1 (en) 2021-10-28 2023-05-04 Gilead Sciences, Inc. Pyridizin-3(2h)-one derivatives
CN118201941A (en) 2021-10-29 2024-06-14 吉利德科学公司 CD73 compounds
CN116143902B (en) * 2021-11-19 2024-06-07 杭州尚健生物技术有限公司 SIRP alpha variants and uses thereof
AU2022417491A1 (en) 2021-12-22 2024-05-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
CA3239528A1 (en) 2021-12-22 2023-06-29 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
KR20230105583A (en) * 2022-01-04 2023-07-11 비피진 주식회사 Polynucleotide for treatment cancer encoding 5'-nucleotidase modified protein
TW202340168A (en) 2022-01-28 2023-10-16 美商基利科學股份有限公司 Parp7 inhibitors
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof
US20230355796A1 (en) 2022-03-24 2023-11-09 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
TW202345901A (en) 2022-04-05 2023-12-01 美商基利科學股份有限公司 Combination therapy for treating colorectal cancer
WO2023205719A1 (en) 2022-04-21 2023-10-26 Gilead Sciences, Inc. Kras g12d modulating compounds
WO2024006929A1 (en) 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024015741A1 (en) 2022-07-12 2024-01-18 Gilead Sciences, Inc. Hiv immunogenic polypeptides and vaccines and uses thereof
US20240091351A1 (en) 2022-09-21 2024-03-21 Gilead Sciences, Inc. FOCAL IONIZING RADIATION AND CD47/SIRPa DISRUPTION ANTICANCER COMBINATION THERAPY

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010070047A1 (en) 2008-12-19 2010-06-24 Novartis Ag Soluble polypeptides for use in treating autoimmune and inflammatory disorders
CA2983972C (en) * 2009-05-15 2023-05-02 University Health Network Compositions and methods for treating hematologic cancers targeting the sirp.alpha.-cd47 interaction
CN110066341B (en) * 2012-12-17 2023-01-31 Pf阿根图姆知识产权控股有限责任公司 Proteins, conjugates, pharmaceutical compositions, DNA constructs, host cells, and methods of making human SIRP alpha fusion proteins
DK3063275T3 (en) * 2013-10-31 2019-11-25 Resolve Therapeutics Llc THERAPEUTIC NUCLEASE ALBUMIN MERGERS AND PROCEDURES
JP6764858B2 (en) * 2014-08-15 2020-10-07 メルク パテント ゲーエムベーハー SIRP-alpha immunoglobulin fusion protein
CN106146670B (en) * 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 A kind of new recombination double functions fusion protein and its preparation and application
GEP20227447B (en) * 2015-08-07 2022-12-12 Alx Oncology Inc Constructs having sirp-alpha domain or variant thereof
WO2018014068A1 (en) * 2016-07-19 2018-01-25 Teva Pharmaceuticals Australia Pty Ltd Attenuated type i ifn cd47 combination therapy
CA3071193A1 (en) * 2017-07-26 2019-01-31 Forty Seven, Inc. Anti-sirp-alpha antibodies and related methods

Also Published As

Publication number Publication date
AU2019256177A1 (en) 2020-11-26
US11891423B2 (en) 2024-02-06
US20210171593A1 (en) 2021-06-10
KR20210003766A (en) 2021-01-12
TW201943728A (en) 2019-11-16
CN111989346A (en) 2020-11-24
EP3795595A4 (en) 2022-03-16
CN110386984A (en) 2019-10-29
TWI822760B (en) 2023-11-21
EP3795595A1 (en) 2021-03-24
CA3097417A1 (en) 2019-10-24
WO2019201236A1 (en) 2019-10-24
CN110386984B (en) 2022-04-22
JP2021520830A (en) 2021-08-26
BR112020021294A2 (en) 2021-01-26

Similar Documents

Publication Publication Date Title
SG11202010237RA (en) Fusion protein binding to cd47 protein and application thereof
IL268258A (en) Cd47 antigen binding unit and uses thereof
EP3612218A4 (en) Trem2 antigen binding proteins and uses thereof
IL278943A (en) Multi-specific binding proteins and improvements thereon
IL265489B (en) Recombinant binding proteins and their use
EP3544628A4 (en) 4-1bb binding proteins and uses thereof
GB201709537D0 (en) Fusion protein comprising three binding domains to 5ta and cd3
EP3275895A4 (en) Neuropilin-1 specific binding peptide, fusion protein fused with same, and use thereof
EP3290441A4 (en) RGMa BINDING PROTEIN AND USE THEREOF
HK1253533A1 (en) Cd131 binding proteins and uses thereof
IL284679A (en) Multi-functional fusion proteins and uses thereof
EP3722305A4 (en) Hm-3 fusion protein and use thereof
SG11202104912SA (en) Fusion protein and use thereof
IL278102A (en) Fusion proteins containing cd47 antibodies and cytokines
IL275248A (en) Therapeutic enzyme fusion protein having a novel structure and use thereof
SG11202110400QA (en) Fusion protein and use thereof
EP3445394A4 (en) Alk7 binding proteins and uses thereof
EP3836959A4 (en) Anti-angiogenesis fusion protein and uses thereof
EP3805265A4 (en) Antibody binding to tie2 and use thereof
EP3668551A4 (en) Apom-fc fusion proteins and uses thereof
EP4041772A4 (en) Antibodies binding 4-1bb and uses thereof
IL290715A (en) Nkg2d fusion proteins and uses thereof
EP3816181A4 (en) Improved fviii fusion protein and use thereof
EP3700571A4 (en) Alk7 binding proteins and uses thereof
EP3677280A4 (en) Polypeptide and antibody bound to polypeptide